Loading...
Loading...
Shares of
Sarepta Therapeutics IncSRPT were trading higher by 20 percent at one point early Friday morning on no confirmed news reports.
Sarepta's investor relations website showed
no new updates Meanwhile, Twitter users were sharing various theories to explain the unexpected surge in Sarepta's stock.
As a reminder, the U.S. Food and Drug Administrated
decided in late April that the company's drug for the treatment of Duchenne muscular dystrophy (DMD) was not effective. A final vote to approve or decline the drug, eteplirsen, is scheduled for May 26.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsDuchenne Muscular DystrophyeteplirsenFood and Drug AdministrationSareptaSarepta Therapeutics
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
